Voquezna Shortage: What Providers and Prescribers Need to Know in 2026

Since the FDA approval of Voquezna (vonoprazan) tablets in November 2023 and the subsequent expansion of indications to include non-erosive GERD in July 2024, prescribers across gastroenterology and primary care are increasingly selecting vonoprazan as a first-line acid suppressant. However, patient access has not kept pace with prescribing enthusiasm. This guide is written for prescribers who want to understand the access landscape and proactively support patients.

Is There a Voquezna Drug Shortage?

No formal drug shortage has been declared by the FDA or ASHP for vonoprazan. The access challenges your patients are experiencing are not the result of a manufacturing crisis or supply chain disruption. Rather, they reflect the distribution dynamics typical of a newer brand-name specialty drug:

• Inconsistent retail pharmacy stocking of a high-cost brand-name product (~$830–$1,013 retail/month)

• Significant variation in formulary tier placement across PBMs and health plans

• Prior authorization requirements at many plans, including step therapy (PPI failure documentation)

• No generic alternative until patents expire (not expected before 2030)

Current Formulary Landscape

As of 2026, Voquezna has achieved meaningful formulary access among commercial payers. CVS Caremark added vonoprazan to its national formularies, providing coverage to more than 26 million commercially insured members. Express Scripts has similarly listed Voquezna. However:

• Many plans place Voquezna at a non-preferred tier (Tier 3 or higher), creating significant copay burden even with coverage.

• Medicare Part D coverage varies widely by plan; the manufacturer savings card is not available for Medicare/Medicaid patients.

• Step therapy requirements (requiring documented PPI failure before vonoprazan will be covered) are common in commercial and Medicare plans.

Clinical Rationale: When Is Vonoprazan the Right Choice?

Understanding when vonoprazan is clinically superior helps build the medical necessity case for prior authorization. Key differentiators from PPIs:

• Severe erosive esophagitis (LA Grade C/D): The PHALCON-EE trial demonstrated vonoprazan's superiority over lansoprazole in healing Grade C/D EE (92.9% vs. 84.6% at 8 weeks) and maintenance at 24 weeks (difference of 15.7% for Grade C/D maintenance). This is the strongest evidence-based argument for vonoprazan over PPIs.

• PPI-refractory GERD: Studies show vonoprazan achieves healing in 87.5% of patients who failed PPI therapy. Documenting PPI failure before prescribing vonoprazan also satisfies many step therapy requirements.

• H. pylori with clarithromycin-resistant strains: Voquezna Triple Pak and Dual Pak demonstrated superiority over lansoprazole-based triple therapy in clarithromycin-resistant H. pylori.

• CYP2C19 poor metabolizers: PPIs are significantly impacted by CYP2C19 polymorphisms; vonoprazan's mechanism bypasses this genetic variability, providing more consistent acid suppression regardless of metabolizer status.

Strategies to Facilitate Patient Access

The following steps significantly improve the likelihood your patient will successfully fill their Voquezna prescription:

1. E-prescribe to BlinkRx. Direct your staff to e-prescribe Voquezna to "BlinkRx US Boise, Idaho" in your EMR's dropdown. BlinkRx contacts the patient via secure text, verifies insurance, applies savings programs, handles prior auth, and ships the medication — eliminating most access barriers in one step.

2. Document PPI failure explicitly. In the chart, document which PPIs were tried, at what dose, for how long, and why they were inadequate (e.g., persistent Grade C/D EE on endoscopy despite 8 weeks of PPI therapy). This documentation is the foundation of a successful PA.

3. Submit prior authorizations proactively. Don't wait for the pharmacy rejection. Submit the PA when writing the prescription. Reference the endoscopic grade, PPI history, and relevant ACG guideline support for vonoprazan in severe EE.

4. Educate patients about the Savings Card. For commercially insured patients, the Voquezna Savings Card (voquezna.com/savings, 1-833-366-7149) reduces out-of-pocket cost to as little as $25/month. This card is not available for Medicare/Medicaid patients.

5. Direct patients to medfinder for retail pharmacy locating.[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop provides resources specifically for healthcare providers to help their patients locate in-stock medications.

When to Consider PPI Bridging

If access to vonoprazan will be delayed (e.g., pending PA or BlinkRx processing), a PPI bridge may be appropriate for patients with active erosive esophagitis. For most patients, omeprazole 40 mg daily or esomeprazole 40 mg daily provides meaningful acid suppression while Voquezna is being secured. Always document the bridge and the plan to transition.

Key Drug Interactions to Communicate to Patients

Ensure patients are aware of these interactions before dispensing:

• Rilpivirine (contraindicated): Do not prescribe vonoprazan to patients on Edurant, Complera, Juluca, or Odefsey.

• CYP3A inducers (rifampin, carbamazepine, St. John's Wort): Avoid concomitant use; may significantly reduce vonoprazan exposure.

• Clopidogrel: Vonoprazan is a CYP2C19 inhibitor and may reduce clopidogrel's antiplatelet effect via reduced active metabolite formation.

• pH-sensitive drugs: Elevating gastric pH reduces absorption of ketoconazole, itraconazole, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, and iron salts.

The Bottom Line for Prescribers

Voquezna is not in a formal shortage, but patient access barriers are real and require active management. The most impactful steps: e-prescribe via BlinkRx, document PPI failure, and submit PAs proactively. For ongoing patient support resources, visit medfinder.com/providers.